Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 15/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.72 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.72 |
| ▸ | GSK3A | P49840 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497385 | 0.89 | GSK3B (0.70) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13722254 | 0.89 | GSK3B (0.80) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13722726 | 0.85 | GSK3B (0.86) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL82146 | 0.85 | GSK3B (0.75) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13917302 | 0.85 | GSK3B (0.54) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13722127 | 0.84 | GSK3B (0.84) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13721953 | 0.84 | GSK3B (0.84) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL4027349 | 0.84 | GSK3B (0.84) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL497011 | 0.84 | GSK3B (0.72) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL8342393 | 0.84 | GSK3B (0.72) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106045-B2 | 2-morpholino-4-pyrimidone compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MAPT, PSEN1, PSEN2 | GSK3B 459/4885CYP2D6 3161/4885CYP1A2 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.